Clinical Development of an Adoptive T cell Therapy for Triple Negative Breast Cancer

A genetically engineered immune cell, trained to recognise and destroy triple-negative breast cancer cells, is being tested for safety and effectiveness in patients. This matters because triple-negative breast cancer is an aggressive form of the disease that does not respond to targeted biological therapies or hormone treatments. Standard chemotherapy remains the main option, but it damages healthy tissue and causes severe side effects. The therapy in development—adoptive T cell therapy—takes a patient’s own T cells, equips them with a high-affinity T cell receptor that locks onto cancer-specific peptide antigens, and infuses them back to mount a selective attack. Unlike chemotherapy, this approach spares the rest of the body. If the trial succeeds, it could offer a new treatment pathway for patients with late-stage triple-negative breast cancer who currently have few options. The therapy would not replace chemotherapy entirely, but it could improve survival and quality of life by reducing collateral damage to healthy organs. For a disease with no existing targeted treatments, even a modest improvement in efficacy and tolerability would represent a meaningful advance.